SINOVAC BIOTECH LTD
SVA evidence brief
What we can confirm
- Market Cap:
- $644.7M
What it means
What to watch
Prepared research question
What matters most for SVA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SVA
Sinovac Biotech Ltd. (SVA) is a Chinese biopharmaceutical company focused on vaccines and therapeutics, with a pipeline spanning enterovirus, rotavirus, pneumococcal, and tetanus programs, and reported cash of $488.2M as of 2025-12-31 [sec].
Key risk: Unaudited financial results
Market Cap
$644.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 11 clinical trials for SINOVAC BIOTECH LTD.
Sinovac Biotech Ltd. (SVA) is a Chinese biopharmaceutical company focused on vaccines and therapeutics, with a pipeline spanning enterovirus, rotavirus, pneumococcal, and tetanus programs, and reported cash of $488.2M as of 2025-12-31 [sec].
- Cash and equivalents of $488.2M and shareholders' equity of $4,438.9M as of 2025-12-31 [sec].
- Filed its annual report on Form 20-F for fiscal year ended December 31, 2025, on 2026-06-05 [news].
- Active clinical pipeline includes Phase I/II/III trials for tetravalent inactivated enterovirus vaccine, hexavalent rotavirus vaccine, 24-valent pneumococcal conjugate vaccine, and SNA02-48 for tetanus [catalyst].
- Competitor trials noted from Regeneron, AstraZeneca, Merck, and Janssen in cardiovascular, immunology, and oncology spaces [competitor_trial].
What works
- Substantial cash reserves of $488.2M as of 2025-12-31 provide a strong financial buffer for R&D and operations [sec].
- Broad vaccine pipeline with multiple Phase II and III trials (enterovirus, rotavirus, pneumococcal) suggests diversified development efforts [catalyst].
- Longstanding presence as a leading biopharmaceutical provider in China, as stated in corporate filings [news].
What to weigh
- Financial results for second half of 2025 were reported as unaudited and unreviewed, indicating potential transparency or timing issues [news].
- Competitor activity in overlapping therapeutic areas (e.g., Regeneron's factor XI antibody, Merck's HIV PrEP) may intensify market competition [competitor_trial].
- No disclosed revenue, net income, or accumulated deficit figures in the provided chunks, limiting assessment of profitability trends.
From the filings
Quoted directly from source documents.
Phase III trial for tetravalent inactivated enterovirus vaccine
“Placebo-Controlled Phase IIIa Clinical Trial on the Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Children Aged 6 to 71 Months.”
Catalysts
Catalyst timeline
- 2023-09-20 · Phase2_Start: Inactivated Bivalent Enterovirus Vaccine Phase I/II Clinical Trial — Initiated a Phase I/II trial for an inactivated bivalent enterovirus vaccine in healthy adults and children.
- 2024-03-27 · Phase1_Start: Oral Hexavalent Reassorted Rotavirus Live Attenuated Vaccine (Vero Cell) Phase I Clinical Trial — Started a Phase I trial for an oral hexavalent rotavirus vaccine in healthy adults, children, and infants.
- 2025-01-15 · Phase2_Start: Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial — Began a Phase I/II trial for a tetravalent inactivated enterovirus vaccine in healthy adults and children aged 6 months to 12 years.
- 2025-04-28 · Phase2_Start: SNA02-48 Injection Phase I/II Study — Initiated a Phase I/II study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of SNA02-48 in Chinese adults.
- 2025-06-18 · Phase2_Start: 24-valent Pneumococcal Conjugate Vaccine Phase Ib/II Clinical Trial — Started a Phase Ib/II trial for a 24-valent pneumococcal conjugate vaccine in adults aged ≥18 years.
- 2026-03-09 · Phase1_Start: Safety of Different Doses of [vaccine] Phase I Clinical Trial — Began a Phase I trial to evaluate safety of different doses of an unspecified vaccine.
- 2026-06-28 · Phase3_Start: Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) Phase IIIa Clinical Trial — Initiated a Phase IIIa trial for protective efficacy, immunogenicity, and safety of the tetravalent enterovirus vaccine in children aged 6 to 71 months.
- 2026-06-28 · Phase3_Start: SNA02-48 Injection Phase III Clinical Trial — Started a Phase III trial to evaluate efficacy and safety of SNA02-48 in populations with high-risk tetanus exposure.
- 2026-09-01 · Phase3_Start: 13-Valent Pneumococcal Conjugate Vaccine Phase IIIb Clinical Trial — Began a Phase IIIb trial to evaluate lot-to-lot consistency, immunogenicity, and safety of a 13-valent pneumococcal conjugate vaccine in children aged 2 to 5 years.
Risks & what to watch (3)›
Key risks
- Unaudited financial results — Second half 2025 financials reported as unaudited and unreviewed, raising potential reliability concerns [news].
- Competitive pipeline overlap — Multiple competitor trials in cardiovascular, immunology, and oncology may challenge Sinovac's market position [competitor_trial].
- No profitability data disclosed — Absence of revenue, net income, or accumulated deficit figures limits assessment of financial health [sec].
What to watch
- Progress of Phase III trials for tetravalent enterovirus vaccine and SNA02-48 tetanus therapy, with start dates in 2026 [catalyst].
- Any subsequent audited financial filings or updates to the 2025 annual report [news].
- Competitor trial outcomes from Regeneron, AstraZeneca, Merck, and Janssen that may affect Sinovac's pipeline prospects [competitor_trial].
Sources: Catalysts · Competitor trials · News · Generated October 13, 2026 · How we verify sources →
Run SINOVAC BIOTECH LTD through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SINOVAC BIOTECH LTD facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for SINOVAC BIOTECH LTD?
Sinovac Biotech Ltd. (SVA) is a Chinese biopharmaceutical company focused on vaccines and therapeutics, with a pipeline spanning enterovirus, rotavirus, pneumococcal, and tetanus programs, and reported cash of $488.2M as of 2025-12-31 [sec].
What therapeutic areas does SINOVAC BIOTECH LTD focus on?
SINOVAC BIOTECH LTD develops therapies across Immunology, Cardiovascular, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.